Innovating Works

H2020

Cerrada
HORIZON-MISS-2022-CANCER-01-03
Pragmatic clinical trials to optimise treatments for patients with refractory cancers
ExpectedOutcome:While cancer research and innovation have generated novel treatment options, cancer patients across Europe need access to more effective and patient-centred interventions which keep up with increasing demands in a complex and fragmented oncology healthcare landscape with spiralling healthcare costs.
Sólo fondo perdido 6.0M €
Europeo
Mostrando 1 al 20 de 21 resultados
PREVENT: Improving and upscaling primary prevention of cancer by addressing childhood obesity through impleme... ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 "PREVENT improves upscaling of primary interventions for weight control management during childhood and adolescence to reduce cancer risks i...
2023-07-01 - 2027-06-30 | Financiado
CAPTUS: Demonstrating energy intensive industry integrated solutions to produce liquid renewable energy carr... FUNDACION CIRCE CENTRO DE INVESTIGACION DE RECURSOS Y CONSUMOS ENERGETICOS tramitó un HORIZON EUROPE: HORIZON-CL5-2022-D3-02-05 GHG emissions reduction policies to mitigate climate change heavily impact on energy intensive industries, leading to loss of employment and...
2023-06-23 - 2027-05-31 | Financiado
OpenMod4Africa: Open Modelling Toolbox for development of long term pathways for the energy system in Africa SINTEF AS tramitó un HORIZON EUROPE: HORIZON-CL5-2022-D3-02-02 OpenMod4Africa aims to develop an open Toolbox populated with state-of-the-art models for analysing long-term pathways to sustainable, secur...
2023-06-06 - 2026-06-30 | Financiado
LEGATO: Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomize... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Recurrent glioblastoma is an invariably fatal refractory cancer with dismal prognosis. Patients suffer from low quality of life and very bur...
2023-06-01 - 2028-05-31 | Financiado
ONCODIR: ONCODIR – Evidence-based Participatory Decision Making for Cancer Prevention through implementation... ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Colorectal cancer (CRC) is one of the most common cancer types and its increased occurrence may be attributable to adverse health behaviors,...
2023-06-01 - 2026-11-30 | Financiado
STREXIT2: A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Retroperitoneal sarcomas are rare diseases refractory to treatment with dismal prognosis. Surgery is the only standard approach to primary d...
2023-06-01 - 2028-05-31 | Financiado
LIVERATION: Unravelling the impact of Radiofrequency in liver surgery the key to decrease local recurrence? CONSORCIO MAR PARC DE SALUT DE BARCELONA tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Colorectal cancer (CRC) ranks fourth in cancer deaths worldwide. Between 20% and 30% of patients with advanced CRC have liver metastases (CR...
2023-05-08 - 2028-05-31 | Financiado
CPW: Cancer Prevention at Work (CPW): Occupational health surveillance in the implementation of preventio... ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Chronic infections represent a major cause of human cancer: on a global scale, they are responsible for an estimated 13% of human cancers. H...
2023-05-01 - 2027-04-30 | Financiado
IntReALL 2020: International Study for Treatment of Childhood Relapsed ALL 2020 CHARITE UNIVERSITAETSMEDIZIN BERLIN tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct randomize...
2023-05-01 - 2028-04-30 | Financiado
CCI4EU: COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE ORGANISATION OF EUROPEAN CANCER INSTITUTES tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 "Cancer is the second leading cause of death in Europe with an expected increase of about 25% by 2035. A wide and unacceptable variability i...
2023-05-01 - 2026-04-30 | Financiado
CARE1: First line randomized study platform to optimize treatment in patients with metastatic renal cell ca... INSTITUT GUSTAVE ROUSSY tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 In 2020, there were an estimated 431 288 new cases of kidney cancer (Renal Cell Carcinoma, RCC) globally with 138 611 cases in Europe, leadi...
2023-05-01 - 2028-04-30 | Financiado
PragmaTIL: Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in sele... FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and s...
2023-04-28 - 2028-03-31 | Financiado
CO-CAPTAIN: CANCER PREVENTION AMONG INDIVIDUALS WITH MENTAL ILL-HEALTH: CO-ADAPTING AND IMPLEMENTING PATIENT NAV... MEDIZINISCHE UNIVERSITAET WIEN tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-01 Cancer and mental ill-health constitute leading public health problems in Europe, with more than 80 million people reporting mental health i...
2023-04-27 - 2026-05-31 | Financiado
Sagittarius: A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE S... IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 SAGITTARIUS aim to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC). Approximately half of...
2023-04-27 - 2028-06-30 | Financiado
PIECES: TOWARDS LARGE SCALE ADAPTION AND TAILORED IMPLEMENTATION OF EVIDENCE BASED PRIMARY CANCER PREVENTION... INSTITUT CATALA D'ONCOLOGIA tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-01 The high and growing global burden of cancer urges the need for effective implementation of primary cancer prevention (PCP) programmes targe...
2023-04-24 - 2027-05-31 | Financiado
SALVOVAR: A EUROPEAN MULTI-DISCIPLINARY CLINICAL PROJECT MEANT TO IMPROVE THE MANAGEMENT OF PATIENTS WITH POOR... CNRS UMR 5023 tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 The standard medical-and-surgical treatment of ovarian carcinoma patients relies on a systemic chemotherapy (carboplatin-paclitaxel), a tumo...
2023-04-24 - 2028-04-30 | Financiado
IMPORTANT: IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer... OREBRO LANS LANDSTING tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical bene...
2023-04-24 - 2028-04-30 | Financiado
4P-CAN: Personalized CANcer Primary Prevention research through Citizen Participation and digitally enabled... With a strong belief that primary prevention of cancer represents a collective responsibility (citizens, professionals, decision-makers), du...
2023-04-24 - 2027-04-30 | Financiado
DE-ESCALATE: INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHAS... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of...
2023-04-21 - 2028-05-31 | Financiado
IMPACT- AML: Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI IRST SRL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01-03 In IMPACT-AML, a multidisciplinar R/R AML represents a model of high-impact disease, in which no standard of care exists, and where we have...
2023-04-01 - 2028-03-31 | Financiado